MRK vs BMY
By Alex · Tickerpine
Merck & Co., Inc. vs Bristol-Myers Squibb Company, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | BMY |
|---|---|---|
| Price | $147.76 | $63.43 |
| Market cap | $364.26B | $129.66B |
| P/E ratio | 149.3 | 14.1 |
| ROE | 5.06% | 44.01% |
| Profit margin | 3.64% | 18.47% |
| Revenue growth | 4.70% | 6.90% |
| Dividend yield | 2.30% | 3.97% |
| Beta | 0.12 | 0.19 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs BMY in plain English
- MRK is the bigger company — about 2.8× the market cap of BMY.
- BMY is cheaper on earnings (P/E 14.1 vs 149.3).
- BMY earns a higher return on equity (44% vs 5%).
- BMY is growing revenue faster (7% vs 5%).
- BMY has the higher dividend yield (3.97% vs 2.30%).
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
BMY return calculator
See what $1,000 in Bristol-Myers Squibb Company would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.